Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Effective and Safe Cancer Vaccine? Breakthrough Alternative Cancer Treatment Available Through Special Research Program
  • USA - English


News provided by

First Source Interactive

Oct 30, 2013, 06:00 ET

Share this article

Share toX

Share this article

Share toX


Austin, TX (PRWEB) October 30, 2013 -- Despite billions of dollars spent, thousands of clinical trials conducted and hundreds of new pharmaceutical drugs launched, the 50+ year war on cancer has resulted in few victories. Pioneering biomedical scientists at Perseus PCI intend to change that fact with recent approval of an alternative cancer treatment, a therapeutic vaccine, as part of a research program in the Cayman Islands.

It makes a great deal more sense to figure out the mechanisms in the body that stop the cancer and tweak them rather than bomb them with chemotherapy. - Dr. Thomas Wagner, co-founder of Perseus PCI

Post this

Increasingly aggressive regimens of chemotherapy, radiation and surgery have barely moved the needle on death rates for the most common cancers and cause debilitating side effects that often cause death. A breakthrough is clearly needed, and the personalized immunotherapy treatment licensed by Perseus PCI offers compelling new hope to cancer sufferers by teaching the immune system to destroy the engine of cancer inside the body. Based on decades of research from respected scientist, Dr. Thomas Wagner, the therapy arms the immune system to attack the tumor. And it’s achieved while giving patients a quality of life simply not possible with standard treatment protocols.

“This advanced immunotherapy is as far removed from what’s on a hospital’s pharmacy shelves as medicines can get,” says Dr. Wagner. “We are deconstructing and decoding the tumor, and sending the patient’s own T-cells to destroy the systems that supported its spread.”

Dr. Wagner’s work in genetic medicine directed his research to the promise of personalized immunotherapy in the early 1990s. “We learned then that cancer starts in the body 10 times a day, at least, but 99 percent of them are automatically stopped by natural processes. I decided it made a great deal more sense to figure out the mechanisms in the body that stop the cancer and tweak them rather than bomb them with chemotherapy,” he explains.

Toxic, debilitating and ineffective--according to a study in the Journal of Clinical Oncology, the overall contribution of chemotherapy to five-year survival in adult cancer patients is estimated at just 2.1 percent.

The Perseus method inserts the entire molecular content of the patient’s cancerous tumor cells into dendritic cells (special cells that help the immune system recognize cancer). This triggers a massive response by the immune system against that specific type of cancer cell, creating a lifetime immunity to the disease. With immunotherapy, patients experience none of the devastating side effects associated with chemotherapy such as fatigue, hair loss and memory loss.

“Ideally we want to vaccinate at the earliest stages of cancer because we believe we might actually cure the patient’s disease,” asserts Dr. Wagner. “Our research in the U.S. suggests we can extend the late-stage cancer patient’s quality of life and life expectancy, but we can go further.”

The immunotherapy vaccine, now available at the Perseus clinic in the Cayman Islands, has gone through Phases I and II clinical trials in the U.S. for treatment of advanced stage melanoma, renal cell carcinoma and neuroblastoma. Average life expectancy for patients in this category was estimated at three to five months; life span post immunotherapy averaged three years.

Working with a small section of the patient’s solid tumor, and a vial of blood drawn at the first visit, the vaccine is produced in three days, personalized to the patient’s cells. Initial administration of the vaccine takes place on the third day, followed by three subsequent visits at one-month intervals. The only side effects are a low-grade fever.

The cost, which includes preparation and administration of the personalized cancer vaccine, airfare and hotel stays for all four visits, ranges up to $95,000. “Cancer patients frequently spend that much out of pocket for traditional treatments that deplete their resources and severely affect their quality of life,” asserts Dr. Wagner.

Visit http://www.perseuspci.com or call ​866-299-0750.


DR. THOMAS WAGNER, Ph.D., co-founder of Perseus PCI, is a world-renowned biomedical scientist and innovator who has pioneered some of the past half-century’s most significant biomedical technologies. Learn more about Dr. Wagner

*The Perseus PCI cancer vaccine is approved by the Health Practice Commission of the Cayman Islands for research only. Through Orbis Health Solutions, LLC, additional trials of the immunotherapy vaccine are being pursued in the U.S. and Europe.

Danny Katz, First Source Interactive, http://www.firstsourceinteractive.com, (800) 672-1285 Ext: 3, [email protected]

Modal title

Chemotherapy - The Sad Truth
View PDF
Chemotherapy - The Sad Truth
Life Span Extended
View PDF
Life Span Extended
Chemotherapy - The Sad Truth Life Span Extended

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.